TY - JOUR
T1 - Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia
T2 - Results from the SEIFEM 2010-B registry
AU - Pagano, Livio
AU - Caira, Morena
AU - Candoni, Anna
AU - Aversa, Franco
AU - Castagnola, Carlo
AU - Caramatti, Cecilia
AU - Cattaneo, Chiara
AU - Delia, Mario
AU - De Paolis, Maria Rosaria
AU - Di Blasi, Roberta
AU - Di Caprio, Luigi
AU - Fanci, Rosa
AU - Garzia, Mariagrazia
AU - Martino, Bruno
AU - Melillo, Lorella
AU - Mitra, Maria Enza
AU - Nadali, Gianpaolo
AU - Nosari, Annamaria
AU - Picardi, Marco
AU - Potenza, Leonardo
AU - Salutari, Prassede
AU - Trecarichi, Enrico Maria
AU - Tumbarello, Mario
AU - Verga, Luisa
AU - Vianelli, Nicola
AU - Busca, Alessandro
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Background.To analyze the efficacy of antifungal prophylaxis (AFP) with posaconazole and itraconazole in a real-life setting of patients with acute myeloid leukemia (AML) during the first induction of remission.Methods.From January 2010 to June 2011, all patients with newly diagnosed AML were consecutively registered and prospectively monitored at 30 Italian hematological centers. Our analysis focused on adult patients who received intensive chemotherapy and a mold-active AFP for at least 5 days. To determine the efficacy of prophylaxis, invasive fungal disease (IFD) incidence, IFD-attributable mortality, and overall survival were evaluated.Results.In total, 515 patients were included in the present analysis. Posaconazole was the most frequently prescribed drug (260 patients [50]) followed by fluconazole (148 [29]) and itraconazole (93 [18]). When comparing the groups taking posaconazole and itraconazole, there were no significant differences in the baseline clinical characteristics, whereas there were significant differences in the percentage of breakthrough IFDs (18.9 with posaconazole and 38.7 with itraconazole, P
AB - Background.To analyze the efficacy of antifungal prophylaxis (AFP) with posaconazole and itraconazole in a real-life setting of patients with acute myeloid leukemia (AML) during the first induction of remission.Methods.From January 2010 to June 2011, all patients with newly diagnosed AML were consecutively registered and prospectively monitored at 30 Italian hematological centers. Our analysis focused on adult patients who received intensive chemotherapy and a mold-active AFP for at least 5 days. To determine the efficacy of prophylaxis, invasive fungal disease (IFD) incidence, IFD-attributable mortality, and overall survival were evaluated.Results.In total, 515 patients were included in the present analysis. Posaconazole was the most frequently prescribed drug (260 patients [50]) followed by fluconazole (148 [29]) and itraconazole (93 [18]). When comparing the groups taking posaconazole and itraconazole, there were no significant differences in the baseline clinical characteristics, whereas there were significant differences in the percentage of breakthrough IFDs (18.9 with posaconazole and 38.7 with itraconazole, P
UR - http://www.scopus.com/inward/record.url?scp=84869049025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869049025&partnerID=8YFLogxK
U2 - 10.1093/cid/cis773
DO - 10.1093/cid/cis773
M3 - Article
C2 - 22955439
AN - SCOPUS:84869049025
VL - 55
SP - 1515
EP - 1521
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 11
ER -